Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth

Core Insights - Bristol Myers Squibb reported higher fourth-quarter revenue driven by growth in sales of its immuno-oncology treatments, which helped to offset a decline in revenue from some of its older drugs [1] Group 1 - The increase in revenue is attributed to the success of immuno-oncology treatments [1] - Older drugs experienced a decline in revenue, indicating a potential shift in the company's product performance [1]